BioPro Pharmaceutical is an oncology specialty biopharmaceutical company that has infrastructure in the major countries of Asia, targeting pharmaceutical markets totaling US$30 billion. BioPro’s expertise lies in its capability to market in-licensed pharmaceutical products in China and other Asian/Pacific countries. BioPro is unique in having regulatory expertise and marketing know-how applicable to all of Asia.
BioPro Pharmaceutical, Inc. develops, manufactures, and markets biopharmaceutical oncology medicines for cancer and related illness treatment. It provides Gliadel; Vantas, a drug-delivery system that contains the medicine histrelin, which helps to relieve the symptoms of prostate cancer; and PERMIXON Comprimidos. The company offers its products through sales representatives in Asia. It serves small and medium-sized companies in the United States and Europe. The company was founded in 2003 and is based in San Francisco, California with business infrastructure in Taiwan, Korea, China, and South East Asia. As of 2017, BioPro Pharmaceutical, Inc. operates as a subsidiary of PhytoHealth Corp.